Alex Pearson

Alex Pearson

Auto-generated profile, based on publicly available information

Alex Pearson

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Nature Communications
Verified
Journal Article
Open access
NCNeha Chopra
Neha Chopra
HTHolly Tovey
Holly Tovey
APAlex Pearson
Alex Pearson
RCRos Cutts
Ros Cutts
CTChristy Toms
Christy Toms
NTNicholas C. Turner
Nicholas C. Turner
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors in 43 patients with untreated TNBC. The primary end point, decreased Ki67, occured in 12% of TNBC. In secondary end point analyses, HR deficiency was identified in 69% of TNBC with the mutational-signature-based HRDetect assay. Cancers with HRDetect mutational signatures of HR deficiency had a functional defect in HR, assessed by impaired RAD51 foci formation on end of treatment biopsy. Following rucaparib treatment there was no association of Ki67 change with HR deficiency. In contrast, early circulating tumor DNA dynamics identified activity of rucaparib, with end of treatment ctDNA levels suppressed by rucaparib in mutation-signature HR-deficient cancers. In ad hoc analysis, rucaparib induced expression of interferon response genes in HR-deficient cancers. The majority of TNBCs have a defect in DNA repair, identifiable by mutational signature analysis, that may be targetable with PARP inhibitors.

1 February 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
APAlex Pearson
Alex Pearson
PPPaula Z Proszek
Paula Z Proszek
JPJavier Pascual
Javier Pascual
CFCharlotte Fribbens
Charlotte Fribbens
MSMonee K. Shamsher
Monee K. Shamsher
NTNicholas C. Turner
Nicholas C. Turner
Purpose:Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential to acquire mutations with resistance to treatment and disease progression. To identify potentially targetable mutations in advanced breast cancer, we performed prospective molecular characterisation of a cohort of patients with ABC. Experimental Design:Biopsies from patients with advanced breast cancer were sequenced with a 50 gene targeted panel in the Advanced Breast Cancer Biopsy (ABC-Bio) study. Blood samples were collected at disease progression for circulating tumour DNA (ctDNA) analysis, along with matched primary tumour to assess for acquisition in ABC in a subset of patients. Results: We sequenced 210 ABC samples, demonstrating enrichment compared to primary disease for potentially targetable mutations in HER2 (in 6.19% of samples), AKT1 (7.14%) and NF1 (8.10%). Of these enriched mutations, we show that NF1 mutations were frequently acquired in ABC, not present in the original primary disease. In ER positive cancer cell-line models, loss of NF1 resulted in endocrine therapy resistance, through both ER dependent and independent mechanisms. NF1 loss promoted ER-independent cyclin D1 expression, which could be therapeutically targeted with CDK4/6 inhibitors in vitro. Patients with NF1 mutations detected in baseline circulating tumour DNA had a good outcome on the CDK4/6 inhibitor palbociclib and fulvestrant. Conclusions:Our research identifies multiple therapeutic opportunities for advanced breast cancer and identifies the previously underappreciated acquisition of NF1 mutations.

1 January 2021 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JPJavier Pascual
Javier Pascual
JLJoline S.J. Lim
Joline S.J. Lim
IMIain R J Macpherson
Iain R J Macpherson
AAAnne C. Armstrong
Anne C. Armstrong
ARAlistair Ring
Alistair Ring
NTNicholas C. Turner
Nicholas C. Turner
Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in PIK3CA-mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet CDK4/6 inhibitor palbociclib plus selective PI3K inhibitor taselisib in advanced solid tumors, and triplet palbociclib plus taselisib plus fulvestrant in 25 patients with PIK3CA-mutant, ER-positive HER2-negative advanced breast cancer. The triplet therapy response rate in PIK3CA-mutant, ER-positive HER2-negative cancer was 37.5% [95% confidence interval (CI), 18.8–59.4]. Durable disease control was observed in PIK3CA-mutant ER-negative breast cancer and other solid tumors with doublet therapy. Both combinations were well tolerated at pharmacodynamically active doses. In the triplet group, high baseline cyclin E1 expression associated with shorter progression-free survival (PFS; HR = 4.2; 95% CI, 1.3–13.1; P = 0.02). Early circulating tumor DNA (ctDNA) dynamics demonstrated high on-treatment ctDNA association with shorter PFS (HR = 5.2; 95% CI, 1.4–19.4; P = 0.04). Longitudinal plasma ctDNA sequencing provided genomic evolution evidence during triplet therapy.SIGNIFICANCE: The triplet of palbociclib, taselisib, and fulvestrant has promising efficacy in patients with heavily pretreated PIK3CA-mutant ER-positive HER2-negative advanced breast cancer. A subset of patients with PIK3CA-mutant triple-negative breast cancer derived clinical benefit from palbociclib and taselisib doublet, suggesting a potential nonchemotherapy targeted approach for this population.This article is highlighted in the In This Issue feature, p. 1

15 January 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RHRina Hui
Rina Hui
APAlex Pearson
Alex Pearson
Javier CortesJavier Cortes
Javier Cortes
CCChristine Campbell
Christine Campbell
CPCamille Poirot
Camille Poirot
GCGiuseppe Curigliano
Giuseppe Curigliano
Purpose:FGFR1 gene is amplified in 14% of HR+/ HER2- breast cancer patients. Efficacy and safety of lucitanib, an inhibitor of VEGFR1-3, FGFR1-3 and PDGFRα/β, were assessed. Experimental Design: HR+/ HER2- MBC patients received oral lucitanib in 3 centrally confirmed cohorts: 1) FGFR1 amplified, 2) FGFR1 non-amplified, 11q13 amplified, 3) FGFR1 and 11q13 non-amplified. Key inclusion criteria included ECOG PS <2, >1 line of anti-cancer therapy, but <2 lines of chemotherapy. Primary endpoint was ORR by RECIST1.1. Simon's 2-stage design was used: if >2 patients responded among 21 patients, 20 additional patients could be enrolled in each cohort. FGFR1 copy number variation (CNV) were determined by FISH and ddPCR, while FGFR1 expression by IHC. Results: 76 patients (32/18/26 in cohorts 1/2/3) from nine countries were enrolled. The pre-specified primary endpoint was met in cohort 1 with ORR of 19% (95%CI:9-35%), but not in cohorts 2 and 3 with ORR of 0% (0-18%) and 15% (6-34%) respectively. Frequent adverse events included hypertension (87%), hypothyroidism (45%), nausea (33%) and proteinuria (32%). Exploratory biomarker analyses suggested higher ORR in patients with high FGFR1 amplification (>4 CNV) than those without high amplification (22% versus 9%). ORR in patients with FGFR1-high tumors (IHC, H-score >50) was 25% versus 8% in FGFR1-low cancers. Conclusions:Lucitanib had modest antitumor activity and significant hypertension-related toxicity in patients with HR+/ HER2- MBC. Although based on small sample sizes, exploratory biomarker analyses suggested patients with high FGFR1 amplification or expression might derive greater benefit.

17 November 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
BKBelinda Kingston
Belinda Kingston
APAlex Pearson
Alex Pearson
MHMaria Teresa Herrera-Abreu
Maria Teresa Herrera-Abreu
LSLi-Xuan Sim
Li-Xuan Sim
RCRosalind J. Cutts
Rosalind J. Cutts
NTNicholas C. Turner
Nicholas C. Turner
Fulvestrant is used to treat patients with hormone receptor–positive advanced breast cancer, but acquired resistance is poorly understood. PlasmaMATCH Cohort A (NCT03182634) investigated the activity of fulvestrant in patients with activating ESR1 mutations in circulating tumor DNA (ctDNA). Baseline ESR1 mutations Y537S are associated with poor outcomes and Y537C with good outcomes. Sequencing of baseline and EOT ctDNA samples (n = 69) revealed 3/69 (4%) patients acquired novel ESR1 F404 mutations (F404L, F404I, and F404V), in cis with activating mutations. In silico modeling revealed that ESR1 F404 contributes to fulvestrant binding to estrogen receptor–alpha (ERα) through a pi-stacking bond, with mutations disrupting this bond. In vitro analysis demonstrated that single F404L, E380Q, and D538G models were less sensitive to fulvestrant, whereas compound mutations D538G + F404L and E380Q + F404L were resistant. Several oral ERα degraders were active against compound mutant models. We have identified a resistance mechanism specific to fulvestrant that can be targeted by treatments in clinical development. Significance: Novel F404 ESR1 mutations may be acquired to cause overt resistance to fulvestrant when combined with preexisting activating ESR1 mutations. Novel combinations of mutations in the ER ligand binding domain may cause drug-specific resistance, emphasizing the potential of similar drug-specific mutations to impact the efficacy of oral ER degraders in development. This article is featured in Selected Articles from This Issue, p. 201

29 September 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ARAlistair Ring
Alistair Ring
LKLucy S. Kilburn
Lucy S. Kilburn
APAlex Pearson
Alex Pearson
LMLaura Moretti
Laura Moretti
AAAngelica Afshari-Mehr
Angelica Afshari-Mehr
NTNicholas C. Turner
Nicholas C. Turner
Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related (ATR) protein. This phase II study examined the activity of the combination of PARP inhibitor, olaparib, and ATR inhibitor, ceralasertib (AZD6738), in patients with advanced TNBC. Patients and Methods: Patients with TNBC on most recent biopsy who had received 1 or 2 lines of chemotherapy for advanced disease or had relapsed within 12 months of (neo)adjuvant chemotherapy were eligible. Treatment was olaparib 300 mg twice a day continuously and celarasertib 160 mg on days 1–7 on a 28-day cycle until disease progression. The primary endpoint was confirmed objective response rate (ORR). Tissue and plasma biomarker analyses were preplanned to identify predictors of response. Results: 70 evaluable patients were enrolled. Germline BRCA1/2 mutations were present in 10 (14%) patients and 3 (4%) patients had somatic BRCA mutations. The confirmed ORR was 12/70; 17.1% (95% confidence interval, 10.4–25.5). Responses were observed in patients without germline or somatic BRCA1/2 mutations, including patients with mutations in other homologous recombination repair genes and tumors with functional homologous recombination deficiency by RAD51 foci. Conclusions: The response rate to olaparib and ceralasertib did not meet prespecified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to olaparib monotherapy.